The Role of Gonadotropins in Ovulation Induction for PCOS Patients

Polycystic Ovary Syndrome (PCOS) affects approximately 5–10% of women of reproductive age, making it one of the most common endocrine disorders in this population. A hallmark of PCOS is chronic anovulation or oligo-ovulation, which significantly contributes to infertility. Ovulation induction (OI) is a cornerstone of fertility treatment for these women, and while oral agents such as clomiphene citrate and letrozole are often first-line therapies, up to 20–25% of PCOS patients do not ovulate adequately on these medications or fail to conceive despite ovulation. In such cases, gonadotropins become an essential tool for achieving follicular development and pregnancy. This article provides a comprehensive, evidence-based overview of gonadotropin use for ovulation induction in PCOS patients, covering pharmacology, clinical protocols, monitoring, risks, and outcomes.

Understanding Gonadotropins: Types and Mechanisms

Gonadotropins are hormones that act directly on the ovaries to stimulate follicular growth and maturation. The two primary gonadotropins used in reproductive medicine are follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Both are glycoprotein hormones produced by the anterior pituitary gland under the control of gonadotropin-releasing hormone (GnRH) from the hypothalamus. In the context of ovulation induction, exogenous gonadotropins are administered to mimic the natural hormonal cascade and promote the development of one or more mature follicles capable of releasing an egg.

Types of Gonadotropin Preparations

  • Urinary-derived gonadotropins: Extracted from the urine of postmenopausal women (e.g., human menopausal gonadotropin or hMG, which contains both FSH and LH activity). These have been used for decades and are still available in some formulations.
  • Recombinant gonadotropins: Produced via recombinant DNA technology, offering high purity and batch-to-batch consistency. Common examples include recombinant FSH (rFSH, e.g., follitropin alfa, follitropin beta) and recombinant LH (rLH, e.g., lutropin alfa).
  • Highly purified urinary FSH: A refined product with minimal LH contamination (e.g., urofollitropin).
  • Combined preparations: Some formulations contain a fixed ratio of FSH and LH, such as hMG or corifollitropin alfa (a long-acting FSH agonist).

The choice of preparation often depends on patient characteristics, cost, availability, and clinician preference. For PCOS patients, pure FSH formulations are frequently used to minimize LH stimulation, as many PCOS women already have elevated LH levels that can impair follicular quality.

Physiologic Rationale for Gonadotropin Use in PCOS

In women with PCOS, the normal negative feedback mechanisms between ovarian hormones and pituitary gonadotropin secretion are disrupted. Elevated LH relative to FSH, increased androgen production, and insulin resistance conspire to create a hormonal environment that arrests follicular growth. Exogenous FSH overrides this block by directly stimulating granulosa cell proliferation and aromatase activity, leading to estradiol production and follicular maturation. LH, when added, can support the later stages of follicle development and trigger ovulation, but careful dosing is required to avoid premature luteinization or overstimulation.

Indications for Gonadotropin Therapy in PCOS

Gonadotropins are typically reserved for PCOS patients who have failed first-line oral ovulation induction agents or have specific contraindications to them. Common clinical scenarios include:

  • Clomiphene citrate resistance (failure to ovulate after 5 days of 150 mg/day).
  • Clomiphene citrate failure (ovulation achieved but no pregnancy after 3–6 cycles).
  • Letrozole resistance or failure.
  • Intolerance or adverse effects from oral agents (e.g., visual disturbances, mood changes).
  • Need for precise timing of ovulation in conjunction with intrauterine insemination (IUI).
  • History of poor cervical mucus or endometrial thinning with clomiphene.

Additionally, gonadotropins are sometimes used as a second-line treatment in women with PCOS who wish to minimize the risk of multiple pregnancies associated with oral agents, though paradoxically, gonadotropins carry their own risk of multiple gestation. The decision to proceed with gonadotropins must be individualized and made in consultation with a reproductive endocrinologist.

Protocols for Gonadotropin Ovulation Induction in PCOS

Treating PCOS patients with gonadotropins requires a low-dose, step-up protocol to reduce the risk of ovarian hyperstimulation syndrome (OHSS) and multiple follicle development. The goal is to achieve a single dominant follicle. Several protocols have been described:

Low-Dose Step-Up Protocol

  • Starting dose: Typically 37.5–75 IU of FSH per day, sometimes as low as 25 IU for very sensitive patients.
  • Adjustments: The dose is increased by 37.5 IU every 7 days if there is no response (defined as no follicle ≥10 mm).
  • Monitoring: Transvaginal ultrasound and serum estradiol levels are performed every 1–2 days once a lead follicle appears.
  • Trigger: When one or two follicles reach 16–18 mm, human chorionic gonadotropin (hCG) is administered to induce final oocyte maturation and ovulation.
  • Cancellation criteria: If more than two follicles ≥14 mm develop, the cycle may be cancelled or converted to in vitro fertilization (IVF) to avoid high-order multiples.

Alternative Protocols

  • Step-down protocol: Start with a higher dose (150 IU) and reduce it once follicular growth is initiated. This is less commonly used in PCOS due to higher OHSS risk.
  • Chronic low-dose regimen: A fixed low dose (e.g., 37.5 or 50 IU) throughout the cycle without step-up, which can be effective in very sensitive PCOS patients.
  • GNRH agonist trigger: In some cases, especially when OHSS risk is high, a GnRH agonist (e.g., leuprolide acetate) can be used to trigger ovulation instead of hCG, reducing the risk of OHSS.

Close monitoring is crucial. The so-called “FSH threshold” and “FSH window” concepts are key: the dose must be sufficient to raise FSH above the threshold to initiate follicular growth but not so high that it recruits multiple follicles. In PCOS, this window is often narrow, making low-dose protocols essential.

Monitoring During a Gonadotropin Cycle

Patients undergoing gonadotropin ovulation induction require frequent visits to the clinic. Standard monitoring includes:

  • Transvaginal ultrasound: To measure follicular diameter, count the number of developing follicles, and assess endometrial thickness. Typically performed every 1–2 days after the lead follicle reaches 10–12 mm.
  • Serum estradiol (E2): Reflects the functional status of the growing follicles. A rapid rise indicates good response; a plateau or fall suggests impending atresia.
  • LH and progesterone: Sometimes checked to detect premature luteinization, especially in PCOS patients who may have baseline LH elevations.
  • Monitoring for OHSS: Symptoms such as bloating, nausea, ovarian enlargement, or rapid weight gain prompt cycle modification or cancellation.

Standardized guidelines from organisations such as the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) recommend that gonadotropin cycles be performed only by clinicians experienced in their use, with access to immediate ultrasound and laboratory support.

Risks and Complications

While gonadotropins are highly effective, they are not without risks. The most significant complications relevant to PCOS patients are:

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is a potentially life-threatening condition characterised by enlarged ovaries, increased vascular permeability, fluid shift into the third space, ascites, and in severe cases, thromboembolism and renal failure. PCOS patients are at increased risk for OHSS because of their larger antral follicle pool and inherent sensitivity to FSH. The incidence of moderate-to-severe OHSS with gonadotropin therapy is reported at 1–5% in low-dose protocols, but can be higher if aggressive dosing is used. Mitigation strategies include:

  • Low-dose step-up protocols.
  • Coasting (withholding gonadotropins while continuing monitoring).
  • GnRH agonist trigger for final maturation.
  • Intravenous fluids and anticoagulation if severe OHSS develops.

Multiple Pregnancy

The risk of multiple gestations with gonadotropin ovulation induction is dose-dependent and can approach 10–20% or more if multiple follicles develop. Monozygotic twinning is also slightly increased. To mitigate this, cycle cancellation criteria are strict. For example, if more than two follicles ≥16 mm are seen, the cycle is often cancelled. Conversion to IVF with elective single embryo transfer is sometimes recommended for high responders.

Other Risks

  • Ovarian torsion (rare, but more likely with enlarged ovaries).
  • Injection site reactions, infection, or allergic reactions.
  • Ectopic pregnancy (risk similar to other fertility treatments).
  • Long-term risk of ovarian epithelial cancer remains inconclusive; current evidence does not support a causal link, but counseling is appropriate.

Success Rates and Outcomes

When used appropriately in PCOS patients, gonadotropin ovulation induction achieves ovulation rates of 70–85% per cycle and pregnancy rates of 15–25% per cycle, with cumulative live birth rates after 3–4 cycles reaching 50–60% in selected populations. Compared to letrozole, a large randomised trial (the PPCOS II trial) found that letrozole was superior to clomiphene, but gonadotropins were not directly compared. However, in clomiphene-resistant women, gonadotropins are clearly effective, with ovulation rates >80% and cumulative pregnancy rates approaching 60% over 3 cycles.

One meta-analysis of 11 randomised trials comparing low-dose gonadotropin protocols in PCOS women found no significant differences between urinary and recombinant FSH in terms of pregnancy rates or OHSS incidence, but the evidence base is limited. Fresh comparisons suggest that pure FSH preparations may lower OHSS risk in this population compared to hMG.

Alternatives to Gonadotropins

Before resorting to gonadotropins, clinicians should always consider other options. The current American College of Obstetricians and Gynecologists (ACOG) and ASRM guidelines recommend:

  • Lifestyle modification: Weight loss of 5–10% can restore ovulation in many PCOS women with obesity.
  • Letrozole: An aromatase inhibitor with excellent ovulation and pregnancy rates, and lower risk of multiple pregnancy compared to clomiphene.
  • Clomiphene citrate: Less effective than letrozole but still widely used.
  • Metformin: While not a primary ovulation induction agent, it can improve ovulation rates when combined with clomiphene or letrozole, especially in insulin-resistant women.
  • Laparoscopic ovarian drilling (LOD): A surgical option for clomiphene-resistant PCOS, avoiding the need for gonadotropins. It reduces androgen production and can restore ovulation. LOD may be considered when gonadotropins are contraindicated or not preferred.
  • In vitro fertilization (IVF): For women who fail multiple gonadotropin-IUI cycles or have additional factors such as tubal disease or male factor. IVF with controlled ovarian hyperstimulation uses higher gonadotropin doses but permits single embryo transfer to minimise multiple pregnancies.

Practical Considerations for Patients

Patients considering gonadotropin therapy should be informed about the cost, time commitment, and emotional burden. A typical cycle involves 10–14 days of daily injections, frequent monitoring visits, and the possibility of cycle cancellation. The cost of gonadotropins and monitoring can be substantial (often $1,000–$3,000 per cycle in the United States), and insurance coverage varies widely. Patients should also be counseled about the signs of OHSS and the importance of prompt reporting.

Clinicians should ensure that patients have realistic expectations. While the chance of pregnancy per cycle is good, it is not 100%, and multiple cycles may be needed. The risk of twins (about 10%) and triplets (1–2%) is higher than with natural conception, so the patient should be prepared for the possibility of a multifetal pregnancy.

Future Directions and Research

Emerging strategies aim to improve the safety and efficacy of gonadotropin use in PCOS. These include:

  • Use of GnRH antagonist protocols to prevent premature LH surges and allow for GnRH agonist trigger.
  • Predictive algorithms using antral follicle count (AFC), anti-Müllerian hormone (AMH), and body mass index (BMI) to personalise starting doses and reduce OHSS risk.
  • Long-acting FSH preparations like corifollitropin alfa, which require only one injection per cycle, but data in PCOS-specific populations are still emerging.
  • In vitro maturation (IVM) of oocytes from PCOS women, which avoids the need for high-dose gonadotropins altogether and dramatically reduces OHSS risk. IVM is still experimental but promising.

Clinicians are encouraged to consult ASRM practice guidelines and ESHRE recommendations for the latest evidence. Additionally, a 2021 Cochrane review concluded that gonadotropins remain a valuable second-line option for ovulation induction in PCOS, but emphasised the need for individualised dosing and careful monitoring.

Conclusion

Gonadotropins are a powerful and effective tool for inducing ovulation in PCOS patients who do not respond to oral agents. Their use requires a thorough understanding of the underlying pathophysiology of PCOS, a commitment to low-dose step-up protocols, and rigorous monitoring to minimise the risks of OHSS and multiple gestations. When managed by an experienced reproductive endocrinologist, gonadotropin ovulation induction can help many women with PCOS achieve their goal of pregnancy. Ongoing research continues to refine best practices and improve patient outcomes.

For further reading, see the Mayo Clinic guide on PCOS and the UpToDate overview of gonadotropin therapy (subscription required).